Makers Laboratories Share Price
Sector: Major Drugs
149.90 +7.80 (5.49%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
147.50
Today’s High
152.00
52 Week Low
114.00
52 Week High
230.00
Key Metrics
- Market Cap (In Cr) 88.5
- Beta 2.52
- Div. Yield (%) 0
- P/B 1.33
- TTM P/E 17.02
- Peg Ratio -
- Sector P/E 26.62
- Open Price 148.15
- Prev Close 142.1
Makers Laboratories Analysis
Price Analysis
-
1 Week-3.86%
-
3 Months-19.85%
-
6 Month0.14%
-
YTD-21.14%
-
1 Year-2.6%
Risk Meter
- 54% Low risk
- 54% Moderate risk
- 54% Balanced Risk
- 54% High risk
- 54% Extreme risk
Makers Laboratories News
Home remedy: Indian pharma bets on domestic brands to fight US generics slowdown
4 min read . 08 Nov 2024Makers Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 104.39
- Selling/ General/ Admin Expenses Total
- 13.94
- Depreciation/ Amortization
- 4.54
- Other Operating Expenses Total
- 34.93
- Total Operating Expense
- 107.84
- Operating Income
- -3.45
- Net Income Before Taxes
- -3.92
- Net Income
- -6.26
- Diluted Normalized EPS
- -10.62
- Period
- 2024
- Total Assets
- 161.26
- Total Liabilities
- 98.21
- Total Equity
- 63.05
- Tangible Book Valueper Share Common Eq
- 104.94
- Period
- 2024
- Cashfrom Operating Activities
- 0.84
- Cashfrom Investing Activities
- -6.89
- Cashfrom Financing Activities
- 5.74
- Net Changein Cash
- -0.31
- Period
- 2023
- Total Revenue
- 101.28
- Selling/ General/ Admin Expenses Total
- 14.73
- Depreciation/ Amortization
- 4.24
- Other Operating Expenses Total
- 28.32
- Total Operating Expense
- 101.82
- Operating Income
- -0.54
- Net Income Before Taxes
- -0.84
- Net Income
- -4.75
- Diluted Normalized EPS
- -8.06
- Period
- 2023
- Total Assets
- 152.3
- Total Liabilities
- 83.09
- Total Equity
- 69.2
- Tangible Book Valueper Share Common Eq
- 116.06
- Period
- 2023
- Cashfrom Operating Activities
- -8.62
- Cashfrom Investing Activities
- 1.25
- Cashfrom Financing Activities
- 5.78
- Net Changein Cash
- -1.59
- Period
- 2022
- Total Revenue
- 126.63
- Selling/ General/ Admin Expenses Total
- 15.01
- Depreciation/ Amortization
- 4.02
- Other Operating Expenses Total
- 30
- Total Operating Expense
- 112.02
- Operating Income
- 14.6
- Net Income Before Taxes
- 15.69
- Net Income
- 4.98
- Diluted Normalized EPS
- 10.44
- Period
- 2022
- Total Assets
- 144.33
- Total Liabilities
- 84.75
- Total Equity
- 59.58
- Tangible Book Valueper Share Common Eq
- 120.71
- Period
- 2022
- Cashfrom Operating Activities
- 8.5
- Cashfrom Investing Activities
- -11.79
- Cashfrom Financing Activities
- 0.33
- Net Changein Cash
- -2.96
- Period
- 2021
- Total Revenue
- 68.64
- Selling/ General/ Admin Expenses Total
- 11.33
- Depreciation/ Amortization
- 4.61
- Other Operating Expenses Total
- 13.08
- Total Operating Expense
- 64.96
- Operating Income
- 3.68
- Net Income Before Taxes
- 2.7
- Net Income
- -0.33
- Diluted Normalized EPS
- -0.64
- Period
- 2021
- Total Assets
- 136.19
- Total Liabilities
- 82.06
- Total Equity
- 54.13
- Tangible Book Valueper Share Common Eq
- 104.98
- Period
- 2021
- Period
- 2020
- Total Revenue
- 51.4
- Selling/ General/ Admin Expenses Total
- 8.89
- Depreciation/ Amortization
- 1.99
- Other Operating Expenses Total
- 7.61
- Total Operating Expense
- 50.26
- Operating Income
- 1.13
- Net Income Before Taxes
- 0.25
- Net Income
- -0.12
- Diluted Normalized EPS
- -0.18
- Period
- 2020
- Total Assets
- 73.88
- Total Liabilities
- 29.26
- Total Equity
- 44.62
- Tangible Book Valueper Share Common Eq
- 86.93
- Period
- 2020
- Cashfrom Operating Activities
- 4.23
- Cashfrom Investing Activities
- -8.43
- Cashfrom Financing Activities
- 2.91
- Net Changein Cash
- -1.29
- Period
- 2019
- Total Revenue
- 46.63
- Selling/ General/ Admin Expenses Total
- 13.28
- Depreciation/ Amortization
- 1.5
- Other Operating Expenses Total
- -1.7
- Total Operating Expense
- 43.75
- Operating Income
- 2.87
- Net Income Before Taxes
- 3.02
- Net Income
- 2.45
- Diluted Normalized EPS
- 4.79
- Period
- 2019
- Total Assets
- 60.01
- Total Liabilities
- 18.31
- Total Equity
- 41.7
- Tangible Book Valueper Share Common Eq
- 81.37
- Period
- 2019
- Cashfrom Operating Activities
- 5.39
- Cashfrom Investing Activities
- -8.31
- Cashfrom Financing Activities
- 3.92
- Net Changein Cash
- 1
- Period
- 2024-12-31
- Total Revenue
- 27.69
- Selling/ General/ Admin Expenses Total
- 3.18
- Depreciation/ Amortization
- 1.31
- Other Operating Expenses Total
- 9.89
- Total Operating Expense
- 27.69
- Operating Income
- 0
- Net Income Before Taxes
- 0.68
- Net Income
- -0.3
- Diluted Normalized EPS
- -0.5
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 29.57
- Selling/ General/ Admin Expenses Total
- 3.65
- Depreciation/ Amortization
- 1.29
- Other Operating Expenses Total
- 11.44
- Total Operating Expense
- 28.56
- Operating Income
- 1.01
- Net Income Before Taxes
- 11.09
- Net Income
- 8.82
- Diluted Normalized EPS
- 14.76
- Period
- 2024-09-30
- Total Assets
- 150.11
- Total Liabilities
- 79.21
- Total Equity
- 70.9
- Tangible Book Valueper Share Common Eq
- 118.36
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1.43
- Cashfrom Investing Activities
- 13.72
- Cashfrom Financing Activities
- -14.43
- Net Changein Cash
- 0.72
- Period
- 2024-06-30
- Total Revenue
- 29.59
- Selling/ General/ Admin Expenses Total
- 3.63
- Depreciation/ Amortization
- 1.28
- Other Operating Expenses Total
- 9.67
- Total Operating Expense
- 29.96
- Operating Income
- -0.36
- Net Income Before Taxes
- -0.47
- Net Income
- -0.98
- Diluted Normalized EPS
- -0.69
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 27.81
- Selling/ General/ Admin Expenses Total
- 3.51
- Depreciation/ Amortization
- 1.15
- Other Operating Expenses Total
- 7.36
- Total Operating Expense
- 28.06
- Operating Income
- -0.25
- Net Income Before Taxes
- -0.38
- Net Income
- -1.29
- Diluted Normalized EPS
- -2.18
- Period
- 2024-03-31
- Total Assets
- 161.26
- Total Liabilities
- 98.21
- Total Equity
- 63.05
- Tangible Book Valueper Share Common Eq
- 104.94
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 0.84
- Cashfrom Investing Activities
- -6.89
- Cashfrom Financing Activities
- 5.74
- Net Changein Cash
- -0.31
- Period
- 2023-12-31
- Total Revenue
- 26.51
- Selling/ General/ Admin Expenses Total
- 3.37
- Depreciation/ Amortization
- 1.16
- Other Operating Expenses Total
- 7.87
- Total Operating Expense
- 27.46
- Operating Income
- -0.95
- Net Income Before Taxes
- -1.12
- Net Income
- -1.54
- Diluted Normalized EPS
- -2.61
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 25.06
- Selling/ General/ Admin Expenses Total
- 3.66
- Depreciation/ Amortization
- 1.13
- Other Operating Expenses Total
- 9.83
- Total Operating Expense
- 26
- Operating Income
- -0.93
- Net Income Before Taxes
- -1.02
- Net Income
- -1.34
- Diluted Normalized EPS
- -2.27
- Period
- 2023-09-30
- Total Assets
- 153.7
- Total Liabilities
- 87.96
- Total Equity
- 65.74
- Tangible Book Valueper Share Common Eq
- 110.28
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -1.92
- Cashfrom Investing Activities
- -0.47
- Cashfrom Financing Activities
- 2.15
- Net Changein Cash
- -0.24
- Period
- 2023-06-30
- Total Revenue
- 25.01
- Selling/ General/ Admin Expenses Total
- 3.39
- Depreciation/ Amortization
- 1.11
- Other Operating Expenses Total
- 9.87
- Total Operating Expense
- 26.32
- Operating Income
- -1.32
- Net Income Before Taxes
- -1.4
- Net Income
- -2.1
- Diluted Normalized EPS
- -3.55
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 29.45
- Selling/ General/ Admin Expenses Total
- 2.89
- Depreciation/ Amortization
- 1.13
- Other Operating Expenses Total
- 9.5
- Total Operating Expense
- 28.8
- Operating Income
- 0.65
- Net Income Before Taxes
- 0.52
- Net Income
- -0.28
- Diluted Normalized EPS
- -0.5
- Period
- 2023-03-31
- Total Assets
- 152.3
- Total Liabilities
- 83.09
- Total Equity
- 69.2
- Tangible Book Valueper Share Common Eq
- 116.06
- Period
- 2023-03-31
- Cashfrom Operating Activities
- -8.62
- Cashfrom Investing Activities
- 1.25
- Cashfrom Financing Activities
- 5.78
- Net Changein Cash
- -1.59
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Makers Laboratories Technical
Moving Average
SMA
- 5 Day148.22
- 10 Day144.65
- 20 Day140.18
- 50 Day143.5
- 100 Day159.77
- 300 Day155.71
Makers Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Bharat Immunologica And Bio Corp
- 23.13
- -0.29
- -1.24
- 35.88
- 19
- 99.88
- Welcure Drugs And Pharmaceutic
- 8.71
- 0.41
- 4.94
- 15.81
- 4.3
- 98
- Makers Laboratories
- 149.9
- 7.8
- 5.49
- 230
- 114
- 88.5
- Ind Swift
- 13.36
- 0.35
- 2.69
- 34.49
- 12.51
- 71.92
- Zenlabs Ethica
- 31.5
- -2.3
- -6.8
- 52.4
- 27.33
- 20.5
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Bharat Immunologica And Bio Corp
- -
- 1.15
- -23.67
- -16.7
- Welcure Drugs And Pharmaceutic
- -
- 8.37
- -6.66
- -49.3
- Makers Laboratories
- -
- 1.33
- -2.32
- 1.31
- Ind Swift
- 3.78
- -
- -
- -1.44
- Zenlabs Ethica
- 52.24
- 2.17
- 4.16
- 0.59
Makers Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-Jan-25
- Quarterly Results
- 29-Oct-24
- Quarterly Results
- 06-Aug-24
- Quarterly Results
- 23-May-24
- Audited Results
- 13-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 22-May-23
- Audited Results
- 13-Feb-23
- Quarterly Results
- 14-Nov-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 06-Aug-24
- 11-Jul-24
- AGM
- 14-Aug-23
- 22-May-23
- AGM
- 18-Aug-21
- 22-Jul-21
- AGM



- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 10-Nov-21
- 01-Apr-22
- 30-Mar-22
- 1:5
- 10
- 140
- Rights issue of equity shares of Rs. 10/- each in the ratio of 1:5 @ premium of Rs. 140/-.